Skip to Content
Søk Menu

EHA l European Hematology Association’s Annual Congress

EHA 2025

Azacitidine was generally well tolerated in patients ≥ 75 years of age in QUAZAR AML-001

  • / BestPractice Nordic

Fredrik Hellem Schjesvold

EHA 2025: Real-World Insights on Belantamab Mafodotin in RRMM

/ Fredrik Schjesvold
EHA25Myelomatose Play the Video
Malin Rasmussen

EHA 2025: Radiotherapy in FL Linked to Low Relapse Rates

/ Malin Rasmussen
EHA25Lymfom Play the Video

EHA 2025: Improved Outcomes in High-Risk MCL with Acalabrutinib Combination Therapy 

/ Jan Andreasen
EHA25
Carl Sandén

EHA 2025: Novel Immune Escape Pathway in AML Identified and Successfully Blocked

/ Carl Sandén
AMLEHA25 Play the Video
Sara Rossetti

EHA 2025: Tripled Cardiac Morbidity Risk After Hodgkin Lymphoma Therapy

/ Sara Rossetti
EHA25Hodgkins lymfom Play the Video
Justinas Daraskevicius

EHA 2025: Overcoming Venetoclax Resistance

/ Justinas Daraskevicius
AMLEHA25 Play the Video
Lydia Scarfò

EHA 2025: First-in-Class BTK Degrader Drives Strong Responses in R/R CLL/SLL

/ Lydia Scarfò
EHA25 Play the Video
Load more

EHA 2024

Several Trials Showed Improvements in the Treatment of Multiple Myeloma

  • / BestPractice Nordic

Gå ikke glipp av de siste nyhetene fra ditt spesialområde

Registrer deg og få nye artikler, MEDtalks og digitale tidsskrifter direkte til din innboks

Få tilgang

Abstract EHA 2024

Several Trials Showed Improvements in the Treatment of Multiple Myeloma

/ Hematologi / BestPractice Nordic

EHA 2024: One of the Most Important for Many Years

/ Hematologi / BestPractice Nordic

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

/ Hematologi / BestPractice Nordic

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

/ Hematologi / BestPractice Nordic

New Data from EHA Shared and Discussed at Danish Evening

/ Hematologi / Jan Andreasen

PD-1 Inhibitors Have Shown Remarkable Efficacy

  • / BestPractice Nordic

Myelomatose

EHA 2025: Real-World Insights on Belantamab Mafodotin in RRMM

/ Hematologi / Fredrik Schjesvold

EHA 2025: Durable Undetectable MRD Responses with Acalabrutinib in CLL

/ Hematologi / Paolo Ghia

EHA 2025: Sonrotoclax + Zanubrutinib Show Durable Responses in R/R CLL/SLL

/ Hematologi / Chan Cheah

EHA 2025: Zanubrutinib Effective as First-Line CLL/SLL Therapy Regardless of del(17p)

/ Hematologi / Paolo Ghia
Hanne Norseth

EHA 2025: TG01 Shows Promise in KRAS-Mutated Myeloma

/ Hanne Norseth
EHA25Myelomatose Play the Video

Mer fra EHA 2024

Maria Eugenia Chollet

Promising Avenues for the Development of Personalized Treatment for FVII Deficiency

/ Maria Eugenia Chollet
EHA24 Play the Video
Hanne Norseth

Vaccinating Against Mutated RAS in Multiple Myeloma

/ Hanne Norseth
EHA24Myelomatose Play the Video
Sergio Martinez Høyer

An Excellent Target with a Wide Therapeutic Window in del(5q) Myeloid Malignancies

/ Sergio Martinez Høyer
EHA24 Play the Video
Frida Bugge Askeland

Treating MRD Relapse After First-Line Treatment May Prolong PFS and OS in Myeloma Patients

/ Frida Bugge Askeland
EHA24Myelomatose Play the Video
Sigrid S. Skånland

From Genomic Precision Medicine to Functional Precision Medicine in Hematology

/ Sigrid S. Skånland
EHA24 Play the Video
Henrik Hjorth-Hansen

Management of CML in Adults: 2024 ELN Recommendations

/ Henrik Hjorth-Hansen
ALLEHA24 Play the Video
Rasmus Rask Kragh Jørgensen

Development of Prediction Models for Survival among Hodgkin Lymphoma Patients

/ Rasmus Rask Kragh Jørgensen
EHA24Hodgkins lymfom Play the Video
Ângela Mesquita

Better Predictor of Treatment Efficacy of Myelodysplastic Syndromes

/ Ângela Sofia Gerós Mesquita
EHA24 Play the Video
Jelena Jelicic

More Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Can Participate in Clinical Studies

/ Jelena Jelicic
EHA24Lymfom Play the Video
Elin Forsgren

Ibrutinib, Lenalidomide, and Rituximab in Relapsed Mantle Cell Lymphoma

/ Elin Forsgren
EHA24Myelomatose Play the Video
Ari Melnick

Presidential Symposium: Unmet Needs in the Lymphoma Field

/ Ari M. Melnick
EHA24Lymfom Play the Video
Bruno Paiva

Presidential Symposium: Innovative Tools for Disease Monitoring in Multiple Myeloma

/ Bruno Paiva
EHA24Myelomatose Play the Video
Load more

Høydepunkter fra EHA 2023

Anna Sureda Balari

Epcoritamab with Rituximab and Lenalidomide (R2) for Patients with High-Risk Follicular Lymphoma

/ Anna Sureda Balari
EHA23Lymfom Play the Video
Mark Levis

Gilteritinib for Patients with Newly Diagnosed AML

/ Mark Levis
EHA23Ernæring Play the Video
Arnon Kater

MURANO Study Supports the Use of Fixed-Duration VenR in R/R CLL

/ Arnon Kater
CLLEHA23 Play the Video
Evangelos Terpos

Daratumumab Combination Shows Positive Responses in Pretreated R/R Multiple Myeloma.

/ Evangelos Terpos
EHA23Myelomatose Play the Video
Ryan Jacobs

News from EHA23 – A Promising Treatment Option for Follicular Lymphoma

/ Ryan Jacobs
EHA23Lymfom Play the Video
Barbara Eichhorst

What is New from EHA23 Regarding Treatment Strategies in First-Line CLL?

/ Barbara Eichhorst
CLLEHA23 Play the Video
Load more

EHA 2022

Phase 1 Results in SIRPα Antibody CC-95251 in Combination with Rituximab in Patients with R/R NHL

/ Hematologi / Paolo Strati

CLL14 study five-year results: Significantly superior efficacy for Ven-Obi

/ Hematologi / Othman Al-Sawaf

Carfilzomib-lenalidomide-dexamethasone konsolidering i myelomatosepasienter

/ Hematologi / Jakob Nordberg Nørgaard

Treatment with RVD + stem cell transplant achieved higher PFS vs RV alone In patients with newly diagnosed multiple myeloma

/ Hematologi / Paul G. Richardson

Novel oral agent with promising result as second-line treatment option for patients with T-Cell Lymphoma

/ Hematologi / Jean-Marie Michot

A new randomized study suggests an improved depth of response and PFS for patients relapsing on Lenalidomide

/ Hematologi / Paul G. Richardson

The main clinical message from the Five-Year Analysis of Murano Study

/ Hematologi / Arnon P. Kater

Longer PFS and higher ORR for frailty patients with R/R Multiple Myeloma treated with PVd than Vd

/ Hematologi / Paul G. Richardson

A new study shows that PTCD and MRD are complementary and necessary for doing a whole assessment on patient-response for myeloma patients

/ Hematologi / Jakob Nordberg Nørgaard

This is what Carsten Niemann concludes from the recent CLL studies

/ Hematologi / Carsten Utoft Niemann

Manageable safety profile and promising efficacy in heavily pretreated patients with R/R Non-Hodgin Lymphoma

/ Hematologi / Jean-Marie Michot

Hva er den beste behandlingen for eldre pasienter med AML?

/ Hematologi / Bjørn Tore Gjertsen

The New Treatment Landscape of Multiple Myeloma in the Perspective of New Front-line Therapies

/ Hematologi / Claudio Cerchione

Gut microbiome dysbiosis could be implicated in the pathogenesis of CLL

/ Hematologi / Tereza Faitova

Ibrutinib keeps on delivering now as first-line treatment for older patients with mantle cell lymphoma

/ Hematologi / BestPractice Nordic

Superior safety profile for decitabine vs chemotherapy for older patient with AML

/ BestPractice Nordic
AMLEHA22

A novel CAR-T cell therapy thas proven highly effective for patients with RRMM

/ BestPractice Nordic
CAR-TEHA22Myelomatose

Behandling af CLL patienter, der også har type 2 diabetes

/ Emelie Hamotal Curovic Rotbain
CLLEHA22Type 2-diabetes Play the Video
Load more

Mer fra EHA

Ny MEDcast-serie

/ BestPractice Nordic
EHA21

Significant improvements in OS and RFS for older patients with AML

/ Farhad Ravandi
AMLEHA21 Play the Video

Iberdomide show promising efficacy in heavily pretreated patients with Relapsed/Refractory Multiple Myeloma

/ Sagar Lonial
EHA21Myelomatose Play the Video
Load more
Back to top